Table I.
AICDA−/− |
Normal Donors |
|||
---|---|---|---|---|
NP | P | NP | P | |
Total number of Rearrangements | 320 | 1150 | 105 | 636 |
Total number of Mutations | 43 | 124 | 627 | 4864 |
Percentage of Sequences Mutated | 39/320* | 104/1150* | 76/105 | 479/636 |
12% | 9% | 71% | 75% | |
Mutation Range | 1−2 | 1−4 | 1−33 | 1−38 |
Mutation Frequency Overall | 43/64081* | 124/230514* | 627/22693 | 4864/152977 |
0.07% | 0.05% | 2.8% | 3.2% | |
Mutation Frequency of Mutated | 43/7799* | 124/19938* | 627/15149 | 4864/113434 |
Rearrangements | 0.6% | 0.6% | 4.1% | 4.3% |
NP = nonproductive rearrangements, P = productive rearrangements. The AICDA−/− data includes CD19+CD27− and CD19+CD27+ sequences from three patients. The control data comes from previous reports of 4 individuals and three different experiments that collected IgM+, IgM+CD5+, IgM+CD5−, IgD+CD27− and IgD−CD27+ B cells which represent normal unmutated and mutated populations in peripheral blood. The mutation frequencies were calculated from the number of mutations/total number of bases analyzed or from the total number of bases analyzed from mutated sequences only.
Significant (p<.0001) difference between AICDA−/− and normal donors.